Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Next Previous
Trial Profile

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvratoxumab (Primary)
  • Indications Staphylococcal infections; Ventilator associated pneumonia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SAATELLITE
  • Sponsors AstraZeneca; MedImmune

Most Recent Events

  • 07 Oct 2021 Turkey and Ireland were the planned locations, according to ClinicalTrials.gov record.
  • 01 Sep 2021 Primary endpoint has not been met (Efficacy endpoint; incidence of S aureus pneumonia at 30 days, as determined by a masked independent endpoint adjudication committee (patients who received suvratoxumab 5000 mg versus those who received placebo) , according to Results published in The Lancet Infectious Diseases
  • 01 Sep 2021 According to Results published in The Lancet Infectious Diseases, based on a review of prespecified interim pharmacokinetic analysis by data monitoring committee, enrolment in Suvratoxumab 2000 mg group was discontinued 1 year after start of the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top